A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater weight loss than daily caloric restriction (DCR) in adults with overweight or obesity. The study included 165 participants (mean age: 42; mean BMI: 34.1 kg/m²; 73.9% female), randomly assigned to either 4:3 IMF (n=84) or DCR (n=81) between January 2018 and April 2021, 125 completed the trial. All participants received a high-intensity behavioral weight loss program, including group support and a recommendation to engage in 300 minutes of moderate-intensity physical activity per week. The 4:3 IMF group fasted 3 nonconsecutive days per week, consuming only 20% of their energy needs (~400-600 kcal/day for women, 500-700 kcal/day for men) and ate freely on the other 4 days. The DCR group reduced daily intake by 34% to match the weekly energy deficit of the IMF group. At 12 months, the 4:3 IMF group lost 2.89 kg more on average than the DCR group in an intention-to-treat analysis. The 4:3 IMF might be an optimal fasting approach, with better adherence potentially driving the greater weight loss. https://www.acpjournals.org/
The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer…
Proton pump inhibitor (PPI) use was modestly associated with incident dementia in older adults (pooled…
Extended follow-up of three major trials consistently shows that an initial invasive strategy does not…
Escitalopram, duloxetine, and agomelatine achieved higher sustained response rates than fluoxetine, while escitalopram and duloxetine…
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
This website uses cookies.